Document Detail

Soluble guanylate cyclase: a potential therapeutic target for heart failure.
MedLine Citation:
PMID:  22622468     Owner:  NLM     Status:  Publisher    
The number of annual hospitalizations for heart failure (HF) and the mortality rates among patients hospitalized for HF remains unacceptably high. The search continues for safe and effective agents that improve outcomes when added to standard therapy. The nitric oxide (NO)-soluble guanylate cyclase (sGC)-cyclic guanosine monophosphate (cGMP) pathway serves an important physiologic role in both vascular and non-vascular tissues, including regulation of myocardial and renal function, and is disrupted in the setting of HF, leading to decreased protection against myocardial injury, ventricular remodeling, and the cardio-renal syndrome. The impaired NO-sGC-cGMP pathway signaling in HF is secondary to reduced NO bioavailability and an alteration in the redox state of sGC, making it unresponsive to NO. Accordingly, increasing directly the activity of sGC is an attractive pharmacologic strategy. With the development of two novel classes of drugs, sGC stimulators and sGC activators, the hypothesis that restoration of NO-sGC-cGMP signaling is beneficial in HF patients can now be tested. Characterization of these agents in pre-clinical and clinical studies has begun with investigations suggesting both hemodynamic effects and organ-protective properties independent of hemodynamic changes. The latter could prove valuable in long-term low-dose therapy in HF patients. This review will explain the role of the NO-sGC-cGMP pathway in HF pathophysiology and outcomes, data obtained with sGC stimulators and sGC activators in pre-clinical and clinical studies, and a plan for the further clinical development to study these agents as HF therapy.
Mihai Gheorghiade; Catherine N Marti; Hani N Sabbah; Lothar Roessig; Stephen J Greene; Michael Böhm; John C Burnett; Umberto Campia; John G F Cleland; Sean P Collins; Gregg C Fonarow; Phillip D Levy; Marco Metra; Bertram Pitt; Piotr Ponikowski; Naoki Sato; Adriaan A Voors; Johannes-Peter Stasch; Javed Butler
Related Documents :
21975128 - Effects of captopril and angiotensin ii receptor blockers (at(1), at(2)) on myocardial ...
8398498 - Study of left and right ventricular function in romano-ward syndrome.
19177258 - Digit ratio (2d:4d) and hand preference for writing in the bbc internet study.
9205668 - Assessing diagnosis in heart failure: which features are any use?
7185248 - Increased susceptibility of the heart to arrhythmia in response to qt-prolongation asso...
19833308 - Early electrocardiographic findings and mr imaging-verified microvascular injury and my...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-5-24
Journal Detail:
Title:  Heart failure reviews     Volume:  -     ISSN:  1573-7322     ISO Abbreviation:  -     Publication Date:  2012 May 
Date Detail:
Created Date:  2012-5-24     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9612481     Medline TA:  Heart Fail Rev     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Center of Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, 645 North Michigan Ave, Suite 1006, Chicago, IL, 60611, USA,
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Structural coloration signals condition, parental investment, and circulating hormone levels in East...
Next Document:  Progression while receiving preoperative chemotherapy should not be an absolute contraindication to ...